Prochymal for Acute Myocardial Infarction

Prochymal is currently being evaluated in clinical trials for the prevention of heart failure resulting from acute myocardial infarction, or heart attack. Prochymal has been demonstrated in animal models to prevent pathologic remodeling or scar formation in the area of the heart. Animal studies have demonstrated the ability of the product to return heart function to near normal levels in as few as 2 months.

Prochymal Preclinical Data

Untreated Control		Prochymal Treated

The circled region denotes the extent of the scar in each image. Left image: Dense scar formation and wall thinning is seen in control hearts. Right image: In contrast, the scar is limited and the ventricle wall remains thick in the hearts of MSC treated animals. These results demonstrate that MSC therapy limits heart wall thinning after myocardial infarction.

Prochymal Clinical Status

Enrollment in a Phase I human clinical trial, to evaluate the safety and efficacy of Prochymal in the treatment of patients with first-time acute myocardial infarction, has been completed.

For more information about Prochymal, please click here.